{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:17:26Z","timestamp":1784207846345,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020206","name":"Shandong Provincial Health Commission","doi-asserted-by":"publisher","award":["tsqn202211351"],"award-info":[{"award-number":["tsqn202211351"]}],"id":[{"id":"10.13039\/501100020206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174181"],"award-info":[{"award-number":["82174181"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28950","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T11:55:10Z","timestamp":1712058910000},"page":"e28950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease-controlled multiple myeloma in a patient with 17p gain and t(4;14): A case report"],"prefix":"10.1016","volume":"10","author":[{"given":"Xinyu","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e28950_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e28950_bib2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/pds.3927","article-title":"Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model","volume":"25","author":"Cid Ruzafa","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e28950_bib3","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28950_bib4","first-page":"870","article-title":"The effect of novel therapies in high\u2010molecular\u2010risk multiple myeloma","volume":"15","author":"Lancman","year":"2017","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28950_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.heliyon.2024.e28950_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28950_bib7","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.2217\/fon-2019-0431","article-title":"Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/refractory multiple myeloma: IKEMA phase III study design","volume":"16","author":"Moreau","year":"2020","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28950_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28950_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28950_bib10","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28950_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/bjh.17499","article-title":"Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics","volume":"194","author":"Harrison","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e28950_bib12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28950_bib13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/genes12060924","article-title":"Cytogenetics of pediatric acute myeloid leukemia: a review of the current knowledge","volume":"12","author":"Quessada","year":"2021","journal-title":"Genes"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28950_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e28950_bib15","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e28950_bib16","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.2147\/DDDT.S267404","article-title":"Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety","volume":"15","author":"Offidani","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28950_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.13835","article-title":"Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis","volume":"109","author":"Spicka","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e28950_bib18","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.heliyon.2024.e28950_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.808886","article-title":"Landscape of TP53 alterations in chronic lymphocytic leukemia via data mining mutation databases","volume":"12","author":"Soussi","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28950_bib20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"10292","key":"10.1016\/j.heliyon.2024.e28950_bib21","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024049818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024049818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:57:10Z","timestamp":1784206630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024049818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405844024049818"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28950","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-controlled multiple myeloma in a patient with 17p gain and t(4;14): A case report","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28950"}}